A mandated safety program regulators rely on to minimize opioid abuse and misuse is not “well suited” to quickly address the ongoing crisis across the U.S. And the shortcomings reflect a lack of cooperation from opioid makers that made it difficult for the Food and Drug Administration to assess key data, according to a new federal government report.
At issue are REMS, or risk evaluation and mitigation strategy programs, which the FDA requires companies to develop when the agency approves a new medicine that may pose a safety risk. When the FDA decides a REMS program is necessary, drug makers must devise a program to provide physician and patient education, sometimes monitor distribution, and send the agency regular assessments.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
